Actively Recruiting
Phase 1 and 2 Randomized, Double-Blind, Placebo-Controlled Study of XmAb942 in Healthy Volunteers and Adults With Moderate-to-Severe Active Ulcerative Colitis
Led by Xencor, Inc. · Updated on 2026-10-30
270
Participants Needed
114
Research Sites
126 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying XmAb942 in a combined Phase 1 and Phase 2 clinical trial involving healthy volunteers and participants with moderately to severely active ulcerative colitis UC. The study aims to evaluate the safety, how the body processes the drug, and how the drug affects the body in healthy individuals, followed by assessing XmAb942s effects in people with UC. This trial is randomized, double-blind, and placebo-controlled, designed to understand the treatments potential in UC. The study has three parts. Part A involves single ascending doses of XmAb942 or placebo given subcutaneously or intravenously to healthy volunteers. Part B includes multiple ascending doses administered intravenously to healthy volunteers. Part C enrolls participants with active UC to receive three different doses of XmAb942 or placebo during a 12-week induction period, followed by a 40-week maintenance period with a single XmAb942 dose, then a 36-week follow-up. Participants will attend scheduled visits for dosing and monitoring throughout the study. Researchers will assess safety by tracking adverse events in healthy volunteers and clinical remission in UC patients using the modified Mayo score and endoscopic evaluation. Additional blood tests will measure drug levels and effects. The total participation duration can extend up to about 72 weeks for UC patients, including treatment and follow-up periods.
CONDITIONS
Brief Title
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Research Team
9
942 Study Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here